Research work · 2014

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B. Garon, Tudor–Eliade Ciuleanu, Oscar G. Arrieta, Kumar Prabhash, Konstantinos Nikolaos Syrigos, Tuncay Göksel, Keunchil Park, Vera A. Gorbunova, Rubén Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyżewicz, С. В. Орлов, Conrad R. Lewanski, Michael Thomas, Paolo Bidoli, Shaker R. Dakhil, Steven J.M. Gans, Joo-Hang Kim, Alexandru Călin Grigorescu, Nina A. Karaseva

The Lancet

Read free full text

DOI: 10.1016/s0140-6736(14)60845-x